BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29449575)

  • 1. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
    Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
    Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
    Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
    Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
    Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
    Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tcrδ translocations that delete the Bcl11b haploinsufficient tumor suppressor gene promote atm-deficient T cell acute lymphoblastic leukemia.
    Ehrlich LA; Yang-Iott K; Bassing CH
    Cell Cycle; 2014; 13(19):3076-82. PubMed ID: 25486566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
    Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
    Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
    Sun S; Fang W
    Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
    Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of karyotyping,
    Sun Y; Tang G; Hu Z; Thakral B; Miranda RN; Medeiros LJ; Wang SA
    J Clin Pathol; 2018 Apr; 71(4):309-315. PubMed ID: 28821581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
    Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of Novel
    Kanagal-Shamanna R; Bao H; Kearney H; Smoley S; Tang Z; Luthra R; Yang H; Zhang S; Lin P; Wu D; Medeiros LJ; Lu X
    Leuk Lymphoma; 2022 Apr; 63(4):865-875. PubMed ID: 34898335
    [No Abstract]   [Full Text] [Related]  

  • 12. SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
    Johansson P; Klein-Hitpass L; Choidas A; Habenberger P; Mahboubi B; Kim B; Bergmann A; Scholtysik R; Brauser M; Lollies A; Siebert R; Zenz T; Dührsen U; Küppers R; Dürig J
    Blood Cancer J; 2018 Jan; 8(1):11. PubMed ID: 29352181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
    Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
    Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia.
    Le Toriellec E; Despouy G; Pierron G; Gaye N; Joiner M; Bellanger D; Vincent-Salomon A; Stern MH
    Blood; 2008 Feb; 111(4):2321-8. PubMed ID: 18073348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.
    Yokohama A; Saitoh A; Nakahashi H; Mitsui T; Koiso H; Kim Y; Uchiumi H; Saitoh T; Handa H; Jimbo T; Murayama K; Sakura T; Murakami H; Karasawa M; Nojima Y; Tsukamoto N
    Int J Hematol; 2012 Jan; 95(1):77-85. PubMed ID: 22189846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL.
    Luo L; Lu FM; Hart S; Foroni L; Rabbani H; Hammarström L; Yuille MR; Catovsky D; Webster AD; Vorechovský I
    Cancer Res; 1998 Jun; 58(11):2293-7. PubMed ID: 9622061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
    Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.
    Vorechovský I; Luo L; Dyer MJ; Catovsky D; Amlot PL; Yaxley JC; Foroni L; Hammarström L; Webster AD; Yuille MA
    Nat Genet; 1997 Sep; 17(1):96-9. PubMed ID: 9288106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATM mutations in sporadic lymphoid tumours.
    Stankovic T; Stewart GS; Byrd P; Fegan C; Moss PA; Taylor AM
    Leuk Lymphoma; 2002 Aug; 43(8):1563-71. PubMed ID: 12400598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.